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Abstract
Background:  The growing field of proteomics and systems biology is resulting in an ever
increasing demand for purified recombinant proteins for structural and functional studies. Here, we
show a systematic approach to successfully express a full-length protein of interest by using cell-
free and cell-based expression systems.
Results: In a pre-screen, we evaluated the expression of 960 human full-length open reading
frames in Escherichia coli (in vivo and in vitro). After analysing the protein expression rate and
solubility, we chose a subset of 87 plasmids yielding no protein product in E. coli in vivo. These
targets were subjected to a more detailed analysis comparing a prokaryotic cell-free E. coli system
with an eukaryotic wheat germ system. In addition, we determined the expression rate, yield and
solubility of those proteins. After sequence optimisation for the E. coli in vitro system and generating
linear templates for wheat germ expression, the success rate of cell-free protein expression
reached 93%.
Conclusion: We have demonstrated that protein expression in cell-free systems is an appropriate
technology for the successful expression of soluble full-length proteins. In our study, wheat germ
expression using a two compartment system is the method of choice as it shows high solubility and
high protein yield.
Background
With the sequencing of the human genome completed
and with mRNA/cDNA identification rapidly progressing,
many potential novel genes have been discovered and
attention has turned to the function and structure of the
predicted proteins [1-4]. In order to study these novel
gene products, sufficient amounts of protein generally
obtained through recombinant protein expression are
required. The (high-throughput) expression and charac-
terisation of unknown and poorly characterised human
proteins is a main objective of recombinant proteomic
studies today.
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Escherichia coli is the most commonly used prokaryotic
expression system for the high-level production of recom-
binant proteins in vivo [5] and has already been used suc-
cessfully in high-throughput protein expression and
purification studies [4,6]. The use of E. coli has many
advantages, including the ease of growth and manipula-
tion of the organism and the availability of many different
vectors and host strains that have been developed over the
years. However, the use of E. coli also has limitations, such
as the aggregation of protein in insoluble inclusion bod-
ies, problems with the expression of gene products toxic
to the physiology of the host cell or proteolytic degrada-
tion of proteins in the cytoplasm [7]. In light of these dif-
ficulties, cell-free expression systems are becoming
increasingly popular [8-14]. The in vitro systems have sev-
eral advantages, including rapid protein synthesis [15],
the possibility to express toxic gene products [16] and
constructs that otherwise would be proteolytically
degraded. Furthermore, it is possible to express proteins
with up to 10 putative transmembrane domains as
reported recently [17]. The compatibility with PCR-gener-
ated templates as well as plasmids allows the in vitro
expression reaction with E. coli extract to be optimised
using silent mutations within PCR products [18]. These
sequence optimisations reduce unfavourable secondary
structures in mRNA and thus improve the success rate of
translation and protein expression. In contrast, for cell-
free protein expression with wheat germ lysate sequence
optimisation is not necessary because of the eukaryotic
nature of this source.
For protein expression analyses, a comprehensive cDNA
collection is available at the German Ressource Center
(RZPD). The full-length open reading frames (ORFs) are
cloned into an entry vector by utilizing the Gateway® clon-
ing technology (Invitrogen). Untranslated regions are
excluded and only the open reading frame is cloned into
the selected vector, either with or without a stop codon.
For protein expression, the open reading frame can be
moved into any desired expression vector by homologous
recombination. Thus, a protein can be expressed with or
without a tag and the tag itself can easily be selected and
altered by choosing the appropriate destination vector.
The aim of this study was to evaluate alternatives to pro-
tein expression in E.coli in vivo especially for those ORFs
yielding no protein in this system. Therefore we investi-
gated protein expression in two different in vitro systems:
E. coli and wheat germ extract. The performance of these
systems was analysed and optimised in respect to expres-
sion rate, protein yield and solubility. Altogether, we
tested the expression of 960 human full-length proteins in
vivo and in vitro using standardised conditions.
Results
Comparison of in vivo and in vitro Escherichia coli 
expressions
We used 960 randomly selected fully sequence-verified
human open reading frames with a broad range of
expected molecular weights (from less than 8 kDa up to
134 kDa, average of 35 kDa), different predicted subcellu-
lar localisations and biochemical functions including
membrane proteins. The ORFs were cloned into an
expression vector (pDEST17-D18), for production of pro-
teins with an N-terminal 6xHis-tag. Identical constructs
were used for protein expression in vitro and also for trans-
formation of bacteria and expression in vivo. Protein
expression was analysed by western blotting using an anti-
His antibody.
In E. coli in vivo 629 out of 960 proteins, and in vitro 456
out of 960 proteins were successfully expressed. Protein
expression in bacteria was unsuccessful either because
clones were generated, which did not show protein
expression (233 samples) or the transformation failed
completely (98 samples). Considering the overlap of both
expression systems, 206 full open reading frames yielded
no protein product in vivo andin vitro. In contrast, 331 tar-
gets were expressed in vivo andin vitro with an average
molecular weight of 33 kDa. Among these, 57 clones
showed an expression rate of 4, 86 clones of 3 and 7
clones of 2. Furthermore, 424 targets expressed in either
system with an average moleclar weight of 32 kDa.
Optimisation of E. coli expression in vitro
We next examined the effect of sequence optimisation on
protein expression rate and protein yield by selecting ran-
domly 87 out of the 960 ORFs (Figure 1, Table 1) where
protein expression had been unsuccessful in vivo or where
transformation had failed in BL21(DE3)pLysS. Three
kinds of linear PCR templates were generated (Figure 2):
(i) a C-terminal wild type with C-terminal 6xHis-tag (ii) a
C-terminal mutant with C-terminal 6xHis-tag and
inserted silent mutation at the N-terminus (iii) a N-termi-
nal wild type with N-terminal 6xHis-tag and no attach-
ment sites (att-sites); For the C- and N-terminal wild type
template the ORF is identical to the original ORF in the
plasmid DNA.
Influence of sequence optimisation on protein expression 
rate
Of these 87 samples, 37 samples (43%) were successfully
expressed in vitro using the original plasmid DNA. After
sequence optimisation, we increased the success rate of
protein expression up to 74 samples (85%) in the cell-free
E. coli system (Figure 3, 4).
When analysing the results of those samples which had
previously not shown expression in vitro (50 samples), weBMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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Table 1: Subset of 87 clones tested in E. coli in vitro and in wheat germ expression. ORF Nr.: Clone identifier; RZPD Clone ID: Available 
clones at RZPD GmbH; Hit Acc. Nr.: Best BLAST hit of DNA sequence. Molecular weight was calculated by translation of the DNA 
sequence. Expression/solubility were assigned values from 0 (no expression/no protein detectable in the supernatant) to 4 (very strong 
band/protein band in the supernatant is stronger than in the pellet). The column 'yielded by' is indicated as follows: WG C: wheat germ 
C-terminal, WG: wheat germ, C- and N-terminal, WG N: wheat germ, N-terminal, RTS CW: E. coli in vitro C-terminal wildtype, RTS 
CM: E. coli in vitro C-terminal mutant, RTS NW: E. coli in vitro N-terminal wildtype, RTS Pl: E. coli in vitro original plasmid.
ORF Nr RZPDCloneID Hit Acc No Gene symbol Mw in kDa Best expr. rate Yielded by Best solubility
264 RZPDo834B052 NM_001677 ATP1B1 36 4 RTS NW 3
400 RZPDo834D022 NM_002573 PAFAH1B3 27 4 WG, RTS CM NW 4
433 NM_000318 PXMP3 32 4 WG, RTS CW CM NW 4
464 RZPDo834F012 NM_006793 PRDX3 29 4 WG C, RTS CM 4
505 NM_003187 TAF9 30 4 WG 3
531 NM_012222 MUTYH 23 4 WG 3
562 RZPDo834B043 NM_000075 CDK4 35 4 RTS CM NW Pl 3
571 RZPDo834B083 NM_003182 TAC1 13 4 WG C, RTS CW CM 4
616 RZPDo834D033 NM_000550 TYRP1 61 3 RTS Pl 2
636 NM_000612 IGF2 22 4 WG C, RTS CW CM 4
637 RZPDo834E013 NM_015646 RAP1B 22 4 WG, RTS CW CM NW 4
639 NM_002512 NME2 14 4 WG N, RTS NW 3
690 RZPDo834F123 NM_006923 SDF2 23 4 WG C, RTS CW CM 4
694 RZPDo834G023 NM_020470 YIF1 32 4 WG N 3
728 RZPDo834E0511 NM_000434 NEU1 46 4 RTS NW 2
741 RZPDo834H073 NM_002799 PSMB7 30 4 WG C 4
772 RZPDo834C0311 NM_002804 PSMC3 46 4 WG N, RTS CM 4
777 RZPDo834C0411 NM_003908 EIF2S2 39 4 WG 4
831 NM_004394 DAP 12 3 WG 4
832 NM_002966 S100A10 12 4 WG, RTS CM NW 4
833 RZPDo834A124 NM_017503 SURF2 30 4 WG C 4
840 RZPDo834B024 NM_005499 UBA2 72 3 WG C 4
842 NM_005942 MOCS1 24 4 WG N, RTS CM 3
855 NM_002134 HMOX2 36 4 RTS NW 4
861 RZPDo834C034 NM_006370 VTI1B 27 4 WG N, RTS NW Pl 3
868 RZPDo834C084 NM_005892 FMNL1 53 4 WG, RTS CM NW 3
873 RZPDo834C104 NM_007363 NONO 55 4 WG C 3
881 NM_002622 PFDN1 15 4 WG C 4
898 RZPDo834D114 NM_006117 PECI 21 4 WG N, RTS CW 4
901 RZPDo834E024 NM_031263 HNRPK 51 4 RTS CW NW 4
904 NM_004401 DFFA 13 4 WG N 4
906 NM_006693 CPSF4 31 4 WG C, RTS CM 4
915 RZPDo834F024 M55654 TBP 38 4 WG N, RTS NW Pl 3
918 NM_004184 WARS 54 3 WG N 4
921 RZPDo834F064 NM_004309 ARHGDIA 23 4 RTS CM NW 3
924 RZPDo834F094 NM_002861 PCYT2 44 4 WG C 4
930 RZPDo834G014 NM_001551 IGBP1 40 4 WG, RTS Pl 4
932 RZPDo834G034 NM_002070 GNAI2 41 4 WG C, RTS NW Pl 4
935 NM_001014835 PAK4 64 2 WG C 3
936 RZPDo834G064 NM_002074 GNB1 38 3 RTS NW 3
939 RZPDo834G074 NM_006321 ARIH2 58 3 WG C, RTS Pl 4
940 RZPDo834G084 NM_013296 GPSM2 55 2 WG C 4
943 RZPDo834G114 NM_001863 COX6B1 11 4 WG, RTS CW CM Pl 4BMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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944 NM_004537 NAP1L1 46 4 WG 4
945 RZPDo834H014 NM_152925 RBM12 59 4 WG C 4
947 RZPDo834H034 NM_001017957 OS-9 70 4 WG C 4
1033 NM_007317 KIF22 74 0 0
1068 NM_206900 RTN2 52 4 WG C 4
1082 NM_018074 FLJ10374 37 4 WG; RTS CW CM 4
1091 NM_001512 GSTA4 26 4 WG 4
1093 RZPDo834A015 NM_001647 APOD 22 4 WG C, RTS CM 4
1101 NM_001643 APOA2 12 4 WG N 3
1115 NM_007261 CMRF-35H 25 4 WG, RTS CM NW 4
1189 RZPDo834H106 NM_001425 EMP3 19 4 WG 4
1294 RZPDo834A035 NM_014876 KIAA0063 24 4 WG 4
1330 NM_002816 PSMD12 53 4 WG C 4
1453 RZPDo834B115 NM_198216 SNRPB 25 4 WG C, RTS CM 3
1454 RZPDo834H0711 NM_006841 SLC38A3 56 4 WG, RTS NW 3
1461 RZPDo834C025 NM_004047 ATP6V0B 22 3 WG C 1
1462 RZPDo834C035 NM_003145 SSR2 21 4 WG C, RTS CM 3
1480 NM_000984 RPL23A 18 3 WG 4
1485 RZPDo834D025 NM_014860 SUPT7L 47 4 WG 4
1487 RZPDo834D035 NM_198120 EBAG9 25 4 WG C 3
1533 RZPDo834F075 NM_013300 HSU79274 31 4 WG C 3
1554 RZPDo834G095 NM_001778 CD48 28 4 RTS NW 3
1555 RZPDo834G105 NM_019111 HLA-DRA 29 4 RTS CM 3
1575 RZPDo834H085 NM_004233 CD83 23 4 WG, RTS CM 4
1576 RZPDo834H095 NM_007024 PL6 39 2 WG N 1
1642 NM_003490 SYN3 64 2 WG 4
1670 NM_006841 SLC38A3 56 4 WG N, RTS NW 3
1734 RZPDo834F0511 NM_001436 FBL 34 4 WG C 4
1736 RZPDo834G0511 NM_004343 CALR 49 4 WG C 4
2066 NM_015723 PNPLA8 89 0 0
2225 RZPDo834H0221 NM_018127 ELAC2 93 0 0
2229 RZPDo834A046 NM_00513 REC8L1 63 3 WG C, RTS CM 4
2504 NM_199053 FLJ12716 65 4 RTS CW CM NW 3
2724 NM_173157 NR4A1 65 4 WG N 2
2871 NM_018099 MLSTD1 60 4 RTS CW CM NW 3
2938 RZPDo834H0421 NM_015072 TTLL5 92 0 0
2949 RZPDo834E1121 NM_020748 KIAA1287 135 0 0
2959 NM_021932 RIC8 17 4 WG, RTS Pl 4
2962 RZPDo834H0621 NM_014149 HSPC049 78 2 RTS CM NW 0
2964 RZPDo834F1121 NM_003263 TLR1 91 4 RTS CM NW 4
2968 RZPDo834G0821 NM_001040428 SPATA7 65 4 RTS CW CM NW 3
2973 NM_032292 FLJ20203 91 4 RTS CW CM NW 3
2978 RZPDo834H0721 NM_014585 SLC40A1 63 0 0
2979 RZPDo834E0821 NM_013277 RACGAP1 71 4 RTS CM 0
Table 1: Subset of 87 clones tested in E. coli in vitro and in wheat germ expression. ORF Nr.: Clone identifier; RZPD Clone ID: Available 
clones at RZPD GmbH; Hit Acc. Nr.: Best BLAST hit of DNA sequence. Molecular weight was calculated by translation of the DNA 
sequence. Expression/solubility were assigned values from 0 (no expression/no protein detectable in the supernatant) to 4 (very strong 
band/protein band in the supernatant is stronger than in the pellet). The column 'yielded by' is indicated as follows: WG C: wheat germ 
C-terminal, WG: wheat germ, C- and N-terminal, WG N: wheat germ, N-terminal, RTS CW: E. coli in vitro C-terminal wildtype, RTS 
CM: E. coli in vitro C-terminal mutant, RTS NW: E. coli in vitro N-terminal wildtype, RTS Pl: E. coli in vitro original plasmid. (Continued)BMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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found that following sequence optimisation 37 (74%)
proteins were expressed.
Influence of sequence optimisation on protein yield
To assess the protein expression yield of PCR products
after sequence optimisation, we evaluated 37 samples that
had previously expressed protein in vitro from original
plasmid DNA. Protein yield was determined by analysis of
protein bands on western blots. Bands were given marks
from 0 (no expression) to 4 (very strong). Here, we dis-
covered that 65% of expressions (24 samples) showed an
improvement in the protein yield compared to expres-
sions using original plasmid DNA and another 19%
showed similar protein yields. A smaller amount of pro-
tein was expressed in only 6 cases (16%) using the opti-
mised PCR products. Among these were 3 samples which
did not express protein at all. In summary, after analysis
of 87 expressions in vitro with optimised PCR-products,
16 samples (18%) revealed no protein product in vivo or
in vitro in the E. coli systems (Table 2).
Wheat germ expression in vitro
The aim of this experiment was to elucidate whether the
wheat germ system would show an increase in the success
rate and protein yield of the 87 selected open reading
frames compared to the optimised in vitro expressions in
E. coli. Two wild type PCR constructs were made for each
open reading frame, one for production of a protein with
a C-terminal 6xHis-tag and another for a protein with a N-
terminal 6xHis-tag (Figure 5). A total of 75 proteins could
be expressed in wheat germ lysate with either a C- or a N-
terminal 6xHis-tag (86%, Figure 3). Out of the 16 open
reading frames which were not expressed in the E. coli sys-
tems, 10 were now successfully expressed using wheat
germ lysate (Table 2). However, 6 open reading frames
did not express in the wheat germ system, but were previ-
ously successfully expressed in vitro in E. coli (Table 2). On
average, based on western blotting analyses, the protein
yield was higher in the wheat germ compared to expres-
sions in the E. coli in vitro system, for identical human
ORFs.
Scheme of the experimental strategy Figure 1
Scheme of the experimental strategy. Successful protein 
expression is indicated by +, unsuccessful protein expression 
by -.
960 full-length
ORFs in
pDest17-D18
E. coli in vivo + + + +
E. coli
in vitro + + + +
37 + + + +
50 − − − −
87 targets
87 targets (37 E. coli in vitro + + + + /50 E. coli in vitro and in vivo − − − −)
E. coli expression in vitro
using optimised linear PCR
products (74 + + + + /13 − − − −)
Wheat germ expression in vitro
using linear PCR products (75 + + + + /12 − − − −)
Comparison of in vitro expression of 87 targets in E. coli and  wheat germ Figure 3
Comparison of in vitro expression of 87 targets in E. coli and 
wheat germ.
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Optimised linear templates for E. coli in vitro expression Figure 2
Optimised linear templates for E. coli in vitro expression. 
Three kinds of linear PCR-products were generated to inves-
tigate the effect on protein expression rate and yield. (i) C-
terminal wild type with C-terminal 6xHis-tag (ii) C-terminal 
mutant with C-terminal 6xHis-tag and inserted silent muta-
tion at the N-terminus (iii) N-terminal wild type with N-ter-
minal 6xHis-tag and no attachment sites (att-sites); For the 
C- and N-terminal wild type template the ORF is identical to 
the original ORF in the plasmid DNA.
(i) C-terminal wild type
(ii) C-terminal mutant
(ii) N-terminal wild type
ORF att1 att2
ORF att1 att2
ORF
silent mutation
6xHis-tagBMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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Table 2: Proteins not expressing in E. coli in vitro or in wheat germ or in both systems. Molecular weight was calculated by translation 
of the DNA sequence. Localization information was taken from the Uniprot database. Domain information was retrieved from the 
Pfam database: cc: coiled coil, tms: transmembrane segment, sp signal peptide. Empty fields correspond to no assignment in the 
database.
Hit Acc. No. Gene symbol Mw in kDa Localization Domains Expression in E. coli in vitro Expression in wheat germ
NM_007317 KIF22 74 nuclear 1cc,, no no
NM_015723 PNPLA8 89 membrane no no
NM_020748 KIAA1287 135 n/a no no
NM_018127 ELAC2 93 nuclear no no
NM_015072 TTLL5 92 n/a 3cc,, no no
NM_014585 SLC40A1 63 membrane ,,10tms no no
NM_020470 YIF1A 32 membrane ,,5tms no yes
NM_004394 DAP 12 secreted no yes
NM_001014835 PAK4 64 n/a no yes
NM_013296 GPSM2 55 n/a no yes
NM_006812 OS-9 70 n/a 1cc1sp1tms no yes
NM_014860 SUPT7L 47 n/a 1cc,, no yes
NM_003908 EIF2S2 39 nuclear no yes
NM_006321 ARIH2 58 nucleus 2cc,, no yes
NM_002816 PSMD12 53 cytosol 1cc,, no yes
NM_000984 RPL23A 18 cytosol no yes
NM_002134 HMOX2 36 microsomal 1cc,1tms yes no
NM_018099 MLSTD1 60 intracellular ,,2tms yes no
NM_013277 RACGAP1 71 intracellular 1cc,, yes no
NM_003263 TLR1 91 membrane 1sp,1tms yes no
NM_032292 FLJ20203 91 n/a 1cc,, yes no
NM_014149 HSPC049 78 n/a 1cc,, yes no
E.coli expression in vitro Figure 4
E.coli expression in vitro. Presented are western blots of 8 targets expressed with C-terminal wild type, C-terminal mutant, N-
terminal wild type and original plasmid DNA templates (from left to right). Successful protein expression was defined for values 
2 – 4 and unsuccessful protein expression for values of 0 and 1. Bands of the expected size are marked with a +.
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Influence of tag position on protein expression in vitro
To assess the influence of either N- or C-terminal tag posi-
tions on expression rate, the 87 open reading frames were
evaluated in both in vitro expression systems, E. coli and
wheat germ (Figure 6). In the E. coli in vitro system, protein
expressions using optimised PCR products were evalu-
ated. Here, 52 (60%) N-terminal tagged wild type PCR
products expressed protein compared to only 30 (34%)
with C-terminal wild type PCR products (Figure 4). With
the C-terminal mutant product 51 (59%) proteins were
expressed. In the wheat germ system, 65 were expressed
using the N-terminal wild type construct (75%) and 67
with the C-terminal tag (78%) (Figure 5).
In summary, 81 out of 87 open reading frames were
expressed in both in vitro systems, corresponding to a suc-
cess rate of 93%. Only 6 ORFs yielded no protein in any
of the systems tested (Table 2).
Comparison of solubility of proteins expressed in E. coli in 
vivo, in vitro and in wheat germ system
For solubility studies, the lysis supernatant of those targets
revealing expression was analysed by western blot. 483
proteins, expressed in E. coli in vivo, were tested and 193
proteins were soluble (40%). For E. coli expressions in
vitro (with original plasmid DNA), 388 were analysed and
185 proteins were soluble (48%). In the wheat germ sys-
Wheat germ expression in vitro Figure 5
Wheat germ expression in vitro. Presented are western blots of 8 targets expressed with C-terminal (left) and N-terminal 
(right) 6xHis-tag. ORF Nr.: clone identifier. GUS: glucuronidase is the positive control. Successful protein expression was 
defined for values 2 – 4 and unsuccessful protein expression for values of 0 and 1. Bands of theexpected size are marked with 
a +.
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Influence of tag on in vitro expression Figure 6
Influence of tag on in vitro expression. We compared 87 tar-
gets expressed in E.coli in vitro and in wheat germ. C-term. 
wt: C-terminal wild type; C-term. mutant: C-terminal 
mutant; N-term. wt: N-terminal wild type.
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tem with a C-terminal 6xHis-tag 66 of the 68 (97%)
expressing PCR products showed soluble protein and
95% with an N-terminal 6xHis-tag.
Discussion and conclusion
With this approach we evaluated the performance of three
different protein expression systems in vivo and in vitro
with a set of 960 full-length open reading frames. For our
investigations of protein synthesis we chose Escherichia
coli bacteria as it is one of the most common and easy to
use systems. For cell-free in vitro expression, we compared
the E. coli with the wheat germ protocol.
First, we analysed the protein expression rate in the two E.
coli systems (in vitro and in vivo) and found that expression
is higher in the in vivo system (66% compared to 48%).
Regarding the success rate of both protocols, only 22% of
plasmids yielded no protein.
We then focused on a subset of 87 targets which had
yielded no protein in E. coli in vivo. These targets expressed
with the cell-free wheat germ and E. coli protocol yielded
very different protein expression rates. In wheat germ 86%
of the targets were expressed and in cell-free E. coli only
43%. One of the reasons for unsuccessful in vitro protein
expression in E. coli may be the presence of secondary
structures in mRNA, which may inhibit translation [19].
To solve this problem, we made use of the ProteoExpert
software, which predicts possible sequence-related prob-
lems and proposes optimised sequences with potentially
reduced unfavourable secondary structures [18,20]. Out
of the 87 proteins that were not expressed in E. coli in vivo,
37 were expressed in vitro using the wild type sequence.
Another set of 37 human proteins could be rescued by
sequence optimisation and using linear templates for in
vitro expression. Therefore, the overall success rate of in
vivo negative clones was 85%. This result clearly demon-
strates that sequence optimisation is necessary to improve
protein synthesis in the E. coli in vitro system.
Furthermore, we analysed the influence of tag position on
protein expression rate. We found no difference between
C- or N-terminal tag in the wheat germ system. However,
considering the cell-free E. coli system, 60% successful
expression was obtained with the N-terminal wild type
PCR product in contrast to only 34% with the C-terminal
one. In this context it is important to realize that this 60%
expression with the N-terminal tag matches with the 59%
obtained with the C-terminal mutant. Obviously, modify-
ing the sequence by adding a sequence optimised peptide
tag also avoids expression problems associated with the
inition of translation.
After analysis of the 87 optimised expressions in vitro, 6
samples remained that were not expressed in vivo or in
vitro (Table 2). This corresponds to a protein expression
success rate of 93%. Regarding those proteins, which
could not be expressed in either system, it is striking that
the molecular mass of all of these targets is higher than 63
kDa with an average molecular weight of 91 kDa. Two
membrane associated proteins belong to the unsuccessful
targets: PNPLA8 (89 kDa) and SLC40A1 (63 kDa), the lat-
ter with more than 10 transmembrane domains. Further-
more, a DNA binding protein KIF22 (74 kDa) of the
Kinesin family, involved in spindle formation, ELAC2 (93
kDa) an endonuclease, TTLL5 (92 kDa), a tubulin tyrosin
ligase-like protein and KIAA1287 (135 kDa), a hypotheti-
cal protein with one transmembrane domain, are among
the non-expressing targets. At this point it is unclear
whether these human proteins are functionally expressed
in any of the systems. Therefore, we can not speculate
about the interference between the protein function and
the different expression systems.
However, 6 proteins with an average molecular weight of
72 kDa were expressed in E. coli in vitro but not in wheat
germ. Among these proteins is HMOX2 which belongs to
the heme oxygenase family, an iron-containing protein
with one transmembrane domain. As reported recently,
iron-containing proteins require supplemented iron
sources which were not added in this case [21]. Further
proteins are two with transmembrane domains (MLSTD1
with two transmembrane domains and TLR1 with one).
The three proteins RACGAP1, FLJ20203 and HSPC049
each contain one coiled coil domain and have molecular
weights higher than 70 kDa. Obviously, the expression of
proteins with molecular weights higher than 70 kDa are
critical for the wheat germ system [22].
Ten proteins with an average molecular weight of 45 kDa
also remain which were expressed in wheat germ but not
in E. coli in vitro. An explanation for this can not be found
in the structural domains, because a coiled coil and one
transmembrane domain were not a hindrance for expres-
sion of the proteins mentioned before. Also the molecular
weight is not the problem. Regarding the function of these
proteins, SUPT7L (transcription regulation factor), EIF2S2
(translation initiation factor) and RPL23A (rRNA binding
protein) are proteins which interfere with DNA or RNA. It
seems that those proteins are likely to have negative effects
on their recombinant expression, when functional active
in E.coli cells. Also proteins influencing the cell cycle like
DAP (involved in cell death), KIAA1142 (has a kinase
motif), PAK4 (kinase, involved in the JNK pathway),
GPSM2 (a signalling modulator) and OS-9 (influences
cell growth viability) seem to hamper recombinant pro-
tein expression.
Based on western blotting analyses, the protein yield in
wheat germ was higher compared to expressions in the E.BMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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coli in vitro. This may be due to the fact that the in vitro E.
coli  expression system is a batch method for protein
expression, whereas the wheat germ system is based on a
two-compartment system. The two chambers are sepa-
rated by a semi-permeable membrane which concentrates
the expressed protein in the 50 μl reaction chamber, but
lets compounds required for protein synthesis such as
substrates and energy components pass through into the
larger feeding chamber. At the same time, potentially
inhibitory by-products are diluted via diffusion across the
membrane. The wheat germ system showed the highest
rate of success compared to expression in E. coli in vitro or
in vivo. Thus, for in vitro protein expression, specifically for
toxic proteins which can not be expressed in bacteria, the
wheat germ system is the method of choice.
Comparing protein solubility in E. coli bacteria and the
cell-free E. coli and wheat germ systems, we found that the
wheat germ system produces the highest solubility rate
(97%). This was also reported previously [22]. It should
be mentioned that our experimental procedure does not
exclude the formation of protein aggregates. Moreover,
the data show that the proteins expressed in vitro are more
likely to be soluble than those expressed in vivo. However,
even though the E. coli in vivo expressions showed, in a
first approach, a higher success rate than in vitro, the in
vitro system does have advantages. Protein expression is
very fast and can be accomplished within a few hours. The
expression of toxic gene products allows proteins to be
expressed, which are impossible to express in bacteria.
Also the use of PCR products is possible, and no clones are
necessary for protein expression. However, linear DNA
needs to be protected during the in vitro reactions to sup-
press nuclease activity. In addition, proteins are also more
likely to be soluble when expressed in any of the in vitro
systems used compared to expression in bacteria.
In summary, we have demonstrated that cell-free protein
expression leads to the desired full-length protein with an
overall success rate of up to 93%. In our study, wheat germ
expression using a two compartment system is the
method of choice as it shows high solubility and high pro-
tein yield.
Methods
Expression-vector construction
The genes used in this study are available from the RZPD
full-ORF clone collection. Entry clones containing the
genes of interest were generated by utilising the Gateway®
Cloning technology (Invitrogen). All entry clones were
fully sequenced in order to verify the insert within
pDONR201. From the entry clone, the ORF was sub-
cloned to a Gateway® destination vector (pDEST17-D18, a
modification of pDEST17, Invitrogen) creating an expres-
sion clone (LR reaction), which was then transformed
into DH10B bacteria. Plasmid DNA of individual clones
was used for transformation of BL21 (DE3) pLysS bacteria
and for protein expression in vivo as well as for protein
expression in the cell-free E. coli system. The pDEST17-
D18 http://www.rzpd.de destination vector was used to
express selected recombinant proteins controlled by the
T7 promoter with an N-terminal 6xHis-tag. Identical con-
structs were used for protein expression in E. coli as well as
for expressions in the cell-free E. coli system. All DNA
preparations were carried out by a Qiagen Biorobot 9600
using Qiawell 96 Ultra Plasmid Kits (Qiagen).
In vivo protein expression using E. coli bacteria
Competent BL21 (DE3) pLysS (Novagen) bacteria were
transformed with plasmid DNA (pDEST17-D18 contain-
ing the gene of interest). The generated expression clones
were cultured overnight, diluted 1:50 to a final volume of
3 ml, and incubated in 24-well plates at 30°C or 3.5 h
(until the OD600 was 0,4–0,6). Expression was induced
with 1 mM IPTG and bacteria cultured for a further 3,5 h
at 30°C. Cells were harvested by centrifugation. A 5 μl
aliquot of cell-pellet was removed and added to 45 μl of
SDS sample buffer. 10 μl of the sample were then loaded
onto a gel for western blotting analysis. An aliquot of the
original sample was also saved for analysis of protein sol-
ubility.
In vitro protein expression (E. coli) using vector DNA
In vitro protein expression was carried out using pDEST17-
D18 plasmid DNA containing the ORF of interest. A cell-
free batch expression system (RTS 100 E. coli HY kit,
Roche Diagnostics) was utilised and 50 μl reactions were
prepared according to the manufacturer's instructions. In
brief, the samples were incubated at 30°C for 4 hours in a
thermal cycler. Green fluorescent protein was expressed as
control protein. Following incubation, a 5 μl aliquot was
removed and added to 45 μl of SDS sample buffer. 10 μl
of sample were then loaded onto a gel for Western blot-
ting analysis. An aliquot of the original sample was also
saved for analysis of protein solubility.
In vitro protein expression (E. coli) using optimised linear 
PCR products
Three PCR products were created for each ORF, a C-termi-
nal wild type, a C-terminal mutant and a N-terminal wild
type product (Figure 2). Sequence-verified templates were
applied for the amplification of PCR products with the
Linear Template Generation Set (LTGS, Roche Diagnos-
tics). For the C-terminal mutant template, silent mutations
as proposed by ProteoExpert http://www.proteoexpert.com
were introduced at the N-terminus of the sequence. PCR
was performed using partially matching primers along the
first 15 to 20 nucleotides of each ORF. One gene-specific
sense primer containing silent mutations, one gene-spe-
cific anti-sense and one wild type primer were used to pro-BMC Biotechnology 2007, 7:64 http://www.biomedcentral.com/1472-6750/7/64
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duce the first PCR product. Different primers were applied
depending on whether a C- or a N-terminal 6xHis-tag was
desired. The PCR products were checked on agarose gels,
and the second amplification step was carried out accord-
ing to the supplier's instructions. As positive control pro-
tein, green fluorescent protein was expressed. Prior to in
vitro expression, all products were verified for correct size
and purity. In vitro expression was carried out according to
instructions and SDS samples prepared.
In vitro protein expression (wheat germ) using linear PCR 
products
Specific PCR products were generated to achieve transla-
tion in wheat germ lysate. The first wild type PCR product
generated for optimisation in the E. coli in vitro system was
utilised to produce a second PCR product for the wheat
germ system. Linear templates with a T7 promoter and a
Kozak sequence were generated for protein expression in
wheat germ lysate. In contrast to PCR products created for
the E. coli in vitro system, these products did not contain
silent mutations. The first PCR products were made using
gene-specific primer pairs and the second amplification
step was carried out by the RTS Wheat Germ LTGS kit
(Roche Diagnostics) according to instructions. The PCR
products were again checked for correct size and purity.
Proteins were expressed using the RTS 100 Wheat Germ
CECF kit (Roche Diagnostics, positive control: glucuroni-
dase) and contained either a C- or an N-terminal 6xHis-
tag. Samples (50 μl) were incubated at 24°C, 900 rpm for
24 h (ProteoMaster Instrument, Roche Diagnostics), SDS
samples prepared for western blotting and an aliquot
saved for analysis of protein solubility.
Analysis of protein solubility
An aliquot of the induced bacterial culture was mixed
with a lysis reagent (Pop Culture Reagent, Novagen) and
0.1% Tween 20 and incubated for 10 min at room temper-
ature. The sample was centrifuged at 10000 g for 20 min,
the supernatant and the pellet were separated and SDS
samples prepared for western blotting analysis. For the in
vitro systems, samples were centrifuged directly and the
pellet and supernatant separated. Results were expressed
as values ranging from 0 (no protein detectable in the
supernatant) to 4 (the protein band in the supernatant is
stronger than in the pellet). Values of 0 to 1 were defined
as insoluble and values of 2 to 4 as soluble protein. Values
correspond to: 4 > 70%; 3 > 40%; 2 > 10%; 1 < 10% solu-
bility; 0 = unsoluble.
Western blotting
Western blotting was performed with the Criterion Sys-
tem (BioRad) and 10–20% gradient pre-cast gels. Samples
(10 μl) were heated at 95°C for 5 min and loaded onto
the gel, which was run at 200 V, 400 mA for 1 h. Following
electrophoresis, gels were blotted onto PVDF membranes
(Hybond P, Amersham Pharmacia) at 100 V, 1000 mA for
1 h and protein transfer checked by briefly immersing the
membrane in Ponceau S solution (Sigma). Membranes
were thoroughly washed in TBST (2 mM Tris/HCl, pH 7.6;
13.7 mM NaCl and 0.1% (v/v) Tween 20) and then
blocked for 1 h in 5% (w/v) non-fat milk/TBST. Following
another 3 × 15 min washes in TBST, membranes were
incubated with the anti-His mouse antibody (Qiagen,
1:2000 in 3% (w/v) bovine serum albumin/TBST) over-
night at 4°C. Following incubation with the secondary
antibody (Anti-mouse IgG HRP, Southern Biotech) for 1
h, membranes were washed three times in TBST and
developed with ChemiGlow® (Alpha Innotech) chemilu-
minescent substrate for 5 min. Images were obtained
using a CCD camera system (ChemiImager 5500, Alpha
Innotech). Protein bands on western blots were assigned
values from 0 (no expression) to 4 (very strong band).
Successful protein expression was defined for values of 2
to 4 and unsuccessful expression for values of 0 and 1. The
ratings reflect the relative amount of human fusion pro-
tein compared to the reference protein (positive control).
4 ≥ reference protein; 3 ≥ 50% of r. p.; 2 ≥ 10% of r. p.; no
expression <1< 10% of r.p.; 0 = no expression.
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